Nail Patella Syndrome: Causes, Symptoms, and Diagnosis

Nail-patella syndrome (NPS) is a rare genetic disorder caused by mutations in the LMX1B gene, and it affects roughly 1 in 50,000 people. The name captures only part of the picture: beyond abnormal nails and missing or underdeveloped kneecaps, the condition can involve the elbows, pelvis, kidneys, and eyes. Because symptoms vary so widely from person to person, some people go years before anyone connects the dots.

What Causes Nail-Patella Syndrome

NPS traces back to mutations in a single gene called LMX1B, located on chromosome 9q34. LMX1B encodes a transcription factor, a protein that helps switch other genes on or off during development. When one copy of this gene is faulty, the body does not produce enough functional LMX1B protein to guide normal formation of limbs, kidneys, and other structures. Researchers describe this mechanism as haploinsufficiency: one working copy simply is not enough.¹

The condition follows an autosomal dominant inheritance pattern, meaning you only need to inherit one mutated copy of LMX1B from one parent to develop it.² If a parent has NPS, each child has a 50 percent chance of inheriting the mutation. But here is a complication that trips up families and clinicians alike: clinical expressivity is highly variable. Two people in the same family carrying the exact same mutation can look quite different. One might have severe knee problems and kidney disease while a sibling has only mildly ridged nails. This variability can make the condition hard to recognize, especially when the more dramatic features happen to be absent.

New mutations also account for a share of cases. Some people with NPS have no family history at all; the mutation arose spontaneously. Evidence of mosaicism in unaffected parents has also been documented, meaning a parent can carry the mutation in only some of their cells and appear completely healthy, yet still pass it on.³

How LMX1B Shapes Limbs and Kidneys

LMX1B plays a critical role in establishing the “top” versus “bottom” of developing limbs. In animal studies, mice lacking Lmx1b entirely failed to develop normal dorsal limb structures: they had no nails and no kneecaps, and their kidneys showed damage similar to what is seen in human NPS.⁴ This is what made the connection between LMX1B and NPS so convincing in the first place: the mouse model recapitulated the human condition almost feature by feature.

In the kidney, LMX1B is essential for the development and ongoing maintenance of podocytes, the specialized cells that wrap around tiny blood-filtering capillaries. Without enough LMX1B, podocyte foot processes and the slit diaphragms between them do not form or function properly.⁵ This explains why kidney problems in NPS are not just a developmental glitch but can worsen over time. The gene is not only needed during fetal development; adult kidneys continue to depend on it.

The Classic Tetrad of Features

Clinicians have traditionally described NPS in terms of four hallmark features, sometimes called the classic tetrad: nail abnormalities, absent or underdeveloped kneecaps, elbow problems, and bony projections from the pelvis called iliac horns.⁶ Not every person with NPS has all four, but recognizing the pattern is usually the fastest route to diagnosis.

Nail Changes

Nail abnormalities are the most common and often the most visible sign. Fingernails tend to be more affected than toenails, and the thumb is typically the worst. Nails may be small, split, ridged, discolored, or absent altogether. A distinctive finding is triangular lunulae, where the pale crescent at the base of the nail appears triangular rather than rounded. The changes are not painful, but they are persistent and often the first thing that prompts a parent or doctor to investigate further.

Kneecap and Elbow Abnormalities

The patellae may be small, irregularly shaped, or completely absent. This underdevelopment leads to patellar instability, and recurrent dislocations or subluxations are common.⁷ People with NPS often describe their kneecaps as feeling loose or “giving way,” particularly during activities that load the joint. At the elbow, common findings include limited ability to fully extend or rotate the forearm and sometimes subluxation of the radial head.⁸

Iliac Horns

Iliac horns are bony protrusions that extend backward from the pelvis. They are considered pathognomonic for NPS, meaning that finding them on an X-ray essentially clinches the diagnosis because they do not occur in other conditions.⁶ Most people never notice them because iliac horns rarely cause symptoms. They are usually discovered incidentally when imaging is done for another reason, or when a clinician specifically looks for them after suspecting NPS.

Kidney Disease in NPS

Kidney involvement is the feature of NPS that carries the most serious health consequences, yet it is also one of the more unpredictable aspects of the condition. Roughly a third of people with NPS show some protein in their urine, which signals that the kidney’s filtering system is not working perfectly.⁹ For most of these individuals, the proteinuria stays mild and does not get worse over time, though they may lose kidney function slightly faster than the general population as they age.

A smaller group, estimated at roughly 5 to 10 percent of all NPS patients, develops heavy proteinuria early in life and progresses to kidney failure.⁹ The timeline is unpredictable: some reach end-stage kidney disease in childhood or young adulthood, while others decline over decades. In one genetically validated series, five out of thirteen patients with NPS nephropathy who had moderate-to-heavy proteinuria went on to develop advanced kidney disease or kidney failure.¹⁰

Under electron microscopy, NPS kidneys show a distinctive pattern: abnormal collagen fibrils and clear, electron-lucent areas within the glomerular basement membrane, the thin sheet that filters blood in the kidney.¹¹ This finding can appear even before any clinical signs of kidney trouble, which is why a kidney biopsy sometimes reveals NPS-related changes in someone who has not yet shown symptoms.

There is currently no targeted treatment for NPS kidney disease. Management focuses on controlling blood pressure, reducing proteinuria with standard kidney-protective medications, and monitoring closely for progression. For those who do reach kidney failure, dialysis and transplantation are options, and importantly, NPS does not recur in a transplanted kidney because the donor organ carries normal LMX1B genes.

Glaucoma and Other Eye Problems

NPS can affect the eyes, and glaucoma is the primary concern. The mechanism is related to the same developmental pathways: LMX1B helps form structures in the front of the eye that regulate fluid drainage. When those structures develop abnormally, pressure can build up and damage the optic nerve over time. In one review of eight families with NPS, a third of participants over age 40 had developed glaucoma.¹² Open-angle glaucoma, the most common type in NPS, tends to develop earlier than it would in the general population. Because glaucoma can steal vision gradually without obvious symptoms, routine screening is important for anyone with NPS.¹³

How NPS Is Diagnosed

Diagnosis is primarily clinical. A physician who recognizes the combination of nail changes and absent or small kneecaps is already most of the way there. Finding iliac horns on a pelvic X-ray essentially confirms it, since those bony projections are not associated with any other known condition.⁶ In practice, the diagnosis often comes after a young person presents with recurrent kneecap dislocations and a sharp-eyed clinician notices the nail abnormalities or orders imaging that reveals the iliac horns.

Genetic testing for LMX1B mutations provides definitive confirmation and is increasingly accessible. In one large study, researchers identified mutations in 37 out of 41 NPS families tested.¹⁴ The fact that about 10 percent of clinically diagnosed families did not have a detectable mutation by standard methods is worth noting. It may reflect limitations of older sequencing technology, or it might point to mutations in regulatory regions of the gene that standard tests miss. Newer approaches, including array-based methods for detecting deletions, have expanded the detection rate.³

Differential diagnosis involves ruling out other conditions that share individual features with NPS. Isolated nail dystrophy, other causes of patellar instability, and various skeletal dysplasias can mimic parts of the picture. But the combination of features, especially the iliac horns, is distinctive enough that competing diagnoses can usually be excluded without extensive testing.¹⁵

Ongoing Monitoring and Management

There is no cure for NPS, and management is focused on surveillance and treating complications as they arise. Current guidelines recommend at least annual monitoring that covers several organ systems simultaneously:

Kidneys: Blood pressure checks, urinalysis, and a first-morning urine test for albumin at least once a year. This catches early kidney involvement before symptoms develop.
Eyes: Glaucoma screening as soon as a child is old enough to cooperate with eye pressure testing, then regularly throughout life.
Joints: Assessment of orthopedic problems, particularly knee stability, elbow range of motion, and any new pain.
Bones: Bone density scans as needed, because some evidence suggests NPS patients may have lower bone mineral density.
Other systems: Assessment for gastrointestinal and neurological symptoms, which some NPS patients experience, and dental exams at least every six months.

This multispecialty approach is recommended because no single doctor typically manages all aspects of the syndrome.¹⁶ A nephrologist, orthopedic surgeon, ophthalmologist, and geneticist may all be involved in the care of one person.

Surgical Options for Knee Problems

Kneecap instability is one of the most functionally limiting aspects of NPS, and surgery is sometimes considered when conservative measures like physical therapy and bracing are not enough. The results, however, are mixed. In a questionnaire-based survey of NPS patients, about half reported patellofemoral instability. Among those who underwent surgery, roughly 87 percent reported improvement in pain, but only 30 percent felt their knee function had improved. Overall patient satisfaction with surgery was around 61 percent, and 10 percent were actively dissatisfied.¹⁷

A particularly sobering finding from the same study: patellar realignment procedures, which are designed to stabilize the kneecap, left about 40 percent of patients with persistent instability, a rate that was no different from patients who did not have surgery. This does not mean surgery is never worthwhile, but it does mean expectations should be carefully managed. The underlying anatomy in NPS is fundamentally abnormal, and standard surgical techniques developed for typical patellar instability may not translate well. Decisions about surgery should involve an orthopedic surgeon who understands the structural peculiarities of NPS knees.⁸

Genetic Counseling and Family Planning

Because NPS is autosomal dominant, genetic counseling is straightforward in most cases: an affected parent has a 50 percent chance of passing the mutation to each child. Prenatal and preimplantation genetic testing is available for families with a known LMX1B mutation. But counseling conversations tend to be complicated by the wide variability in severity. Telling a prospective parent that their child might inherit NPS does not tell them whether the child will have mild nail changes or severe kidney disease. No reliable way currently exists to predict severity based on the type of mutation.

One unusual report described a family from Saudi Arabia where two sisters presented with NPS features, but both parents appeared completely unaffected. Genetic testing revealed that both parents were heterozygous carriers of the same LMX1B mutation (c.268C>T), and both affected daughters were homozygous.¹⁸ This apparent autosomal recessive pattern is extremely rare and challenged the longstanding assumption that NPS is exclusively dominant. Whether the parents’ carrier state produced truly no symptoms or just very subtle ones that went unnoticed is debatable, but the case is a reminder that genetics does not always follow textbook rules neatly.

A Brief History of Discovery

NPS has been recognized as a clinical entity for well over a century, but its genetic story is tied to a landmark in human genetics. Fifty years before modern gene mapping, James Renwick chose NPS as a model to develop methods for linkage analysis in humans. His work revealed that the NPS gene was linked to the ABO blood group gene, making it the third linkage group ever identified in humans.¹⁹ For decades, NPS was diagnosed purely by clinical features and family history. The identification of LMX1B as the causative gene in the late 1990s finally gave the condition a molecular explanation and opened the door to genetic testing. It also connected NPS to a broader family of developmental biology research, since LMX1B homologs in other species were already known to be important for limb patterning. The human genetics and the animal developmental biology converged on the same gene from different directions, which is part of what made the discovery so satisfying to researchers in the field.

LMX1B Mutations Without the Full Syndrome

An interesting wrinkle that has emerged from genetic studies is that not all LMX1B mutations produce classic NPS. Some families carry mutations in LMX1B and develop kidney disease without any of the skeletal or nail features. This condition has been described as isolated LMX1B-associated nephropathy, and it has practical implications for diagnosis. A person presenting with proteinuria and characteristic glomerular basement membrane changes on biopsy could have an LMX1B mutation even if their nails and kneecaps look perfectly normal.² This spectrum from full-blown NPS to kidney-only disease reinforces how variable the effects of LMX1B mutations can be. It also means that the true frequency of LMX1B-related disease may be higher than the traditionally quoted figure for NPS, since some cases fly under the radar as unexplained kidney problems.

1
Human Molecular Genetics. Loss-of-Function Mutations in the LIM-Homeodomain Gene, LMX1B, in Nail-Patella Syndrome
2
PubMed. Spectrum of LMX1B mutations: from nail-patella syndrome to isolated nephropathy
3
Genetics in Medicine. A spectrum of LMX1B mutations in Nail-Patella syndrome: New point mutations, deletion, and evidence of mosaicism in unaffected parents
4
PubMed. Limb and kidney defects in Lmx1b mutant mice suggest an involvement of LMX1B in human nail patella syndrome
5
PubMed Central. LMX1B is essential for the maintenance of differentiated podocytes in adult kidneys
6
PubMed Central. Radiographic findings in the nail-patella syndrome
7
PubMed Central. “Knee-Ding” a Diagnosis: A Case of Nail Patella Syndrome
8
PubMed. Management of patellar problems in skeletally mature patients with nail-patella syndrome
9
PubMed Central. Kidney disease in nail-patella syndrome
10
PubMed Central. Clinical and genetic characterization of nephropathy in patients with nail-patella syndrome
11
PubMed. Nephropathy of nail-patella syndrome
12
PubMed Central. Nail‐patella syndrome and its association with glaucoma: a review of eight families
13
PubMed. Nail-patella syndrome. Overview on clinical and molecular findings
14
The American Journal of Human Genetics. Mutation Analysis of LMX1B Gene in Nail-Patella Syndrome Patients
15
BMJ Case Reports. Diagnosing nail-patella syndrome: can it be so simple?
16
PubMed. Nail-Patella Syndrome
17
PubMed. Nail patella syndrome: Knee symptoms and surgical outcomes. A questionnaire-based survey
18
PubMed Central. Nail-Patella Syndrome: A Case Series From Northern India
19
PubMed. Nail patella syndrome revisited: 50 years after linkage